Determination of dopamine-releasing protein (DARP) in cerebrospinal fluid of patients with neurological disorders.
Levels of DARP in the cerebrospinal fluid (CSF) of patients having a wide variety of neurological disorders were determined. Neurological disorders were categorized as degenerative, demyelinating, epilepsy, trauma, hydrocephalia, inflammatory, A-V malformation, CNS neoplasia, parasitic and stroke. DARP levels were determined by an enzyme-linked immunoabsorbent assay (ELISA) using monoclonal anti-DARP antibodies. A synthetic peptide corresponding to the first 36 aa of the N-terminal of DARP was used as standard. A total of 7 non-neurological patients and 73 patients with neurological disorders were tested. The relative concentrations of DARP decreased in patients with Parkinson's diseases vs. patients with non-neurological diseases and increased in other neuropathologies such as demyelinating, hydrocephalia and A-V malformations. Data obtained suggest that changes in the percentage and concentration of DARP may correlate with certain neurological disorders, showing particularly low levels in Parkinson's disease patients.
Verdugo-Diaz
L
L
Departamento de Fisiología, Facultad de Medicina, Instituto de Fisiología Celular, UNAM, México, D.F., Mexico.
Morgado-Valle
C
C
Solis-Maldonado
G
G
Drucker-Colin
R
R
D005260:Female; D006023:Glycoproteins / Q000134:cerebrospinal fluid*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D009422:Nervous System Diseases / Q000134:cerebrospinal fluid*
D006023:Glycoproteins; D036341:Intercellular Signaling Peptides and Proteins; C058043:dopamine-releasing factor, rat